Search Results

You are looking at 1 - 10 of 187 items for :

  • "oxaliplatin" x
Clear All
Full access

Ludmila Katherine Martin and Tanios Bekaii-Saab

/print certificate. Release date: March 15, 2013; Expiration date: March 15, 2014. Learning Objectives Upon completion of this activity, participants will be able to: Describe the role of oxaliplatin in the management of rectal cancer. Describe the

Full access

Natasha Satkunam, Xuejiao Wei, James J. Biagi, Sulaiman Nanji and Christopher M. Booth

trial demonstrated that the addition of oxaliplatin to 5-FU (FOLFOX) led to improved disease-free survival. 4 Similar findings were observed in a second RCT. 5 Updated analyses of the MOSAIC trial demonstrated oxaliplatin is associated with improved

Full access

Brittany Bauman, Rosemarie Mick, Eileen Martinez, Theresa M. Lawless, Lindsey Zinck, Paige Sinclair, Mary Fuhrer, Mark O’Hara, Charles J. Schneider, Peter O’Dwyer, John Plastaras, Ursina Teitelbaum and Kim A. Reiss

Background Oxaliplatin is a commonly used chemotherapy for patients with gastrointestinal cancers. 1 , 2 A unique and common toxicity of oxaliplatin is oral thermal hyperalgesia (OTH), a form of acute neuropathy caused by disruption of voltage

Full access

Deirdre R. Pachman, Kathryn Ruddy, Lindsey R. Sangaralingham, Axel Grothey, Nilay D. Shah, Andreas S. Beutler, Joleen M. Hubbard and Charles L. Loprinzi

Oxaliplatin-induced peripheral neuropathy is a common toxicity that may last for years, which has resulted in extensive interest in identifying interventions to prevent its occurrence. Administration of intravenous doses of calcium and magnesium

Full access

Eric J Roeland, Thomas W. LeBlanc, Kathryn J. Ruddy, Ryan Nipp, Rebecca Clark-Snow, Rita Wickham, Gary Binder, William L. Bailey, Ravi Potluri, Luke M. Schmerold, Eros Papademetriou and Rudolph M. Navari

+ cyclophosphamide (AC), carboplatin (>14 days apart, as a proxy for AUC ≥4), oxaliplatin (OX), and other non-HEC chemotherapy. We assessed guideline adherence, defined as triple prophylaxis (NK1 RA + 5HT3 RA +dexamethasone) rates at HEC initiation. Results: In 17

Full access

Joseph Rosales and Lucille A. Leong

– 1047 . 10 Levi F Perpoint B Garufi C . Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate . Eur J Cancer 1993 ; 29A : 1280 – 1284 . 11

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook and Christopher Willett

metastatic colorectal cancer treated with cetuximab . Ann Oncol 2008 ; 19 : 508 – 515 . 28 Punt CJ Tol J Rodenburg CJ . Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook and Christopher Willett

radiological response in metastatic colorectal cancer treated with cetuximab . Ann Oncol 2008 ; 19 : 508 – 515 . 34 Punt CJ Tol J Rodenburg CJ . Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in

Full access

Aparna Parikh, Chloe Atreya, W. Michael Korn and Alan P. Venook

with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline. Next-generation sequencing (NGS) of the primary tumor identified HER2 amplification and we were able to obtain trastuzumab-DM1 for off-label use

Full access

Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes and Fernando Rivera

). Doses Administered in Doublets or Triplets Using the PSM-Matched Sample To estimate the possible effect of adding a third drug (anthracycline or docetaxel), oxaliplatin doses were compared in patients who received EOX (epirubicin, oxaliplatin, and